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  Cystatin C is a low molecular mass protein that is passed 
freely through the glomerular membrane. Unlike creatinine, 
cystatin C is eliminated from circulation almost exclusively by 
the kidney and is affected less by renal tubular secretion, theo-
retically making it an ideal marker of glomerular filtration 
rate. A recent meta-analysis suggested serum cystatin C level 
as a better indicator of kidney function than serum creatinine 
level [1]. Cystatin C is produced by all nucleated cells, and its 
level is independent of body composition, in contrast to creati-
nine, which is produced almost exclusively by skeletal muscles 
[2,3]. 
  It has been reported that serum cystatin C level is a strong 
predictor of mortality and cardiovascular events in elderly pa-
tients with chronic renal disease or coronary artery disease 
(CAD) [4,5]. In addition, Maahs et al. [6] reported a statistically 
important relationship between serum cystatin C level and 
CAD in type 1 diabetic patients. In contrast, we found no asso-
ciation between serum cystatin C level and CAD in type 2 dia-
betic patients [7]. Serum cystatin C level was significantly high-
er in patients with diabetic nephropathy, both in CAD patients 
and in non-CAD patients. On the other hand, there was no 
significant difference in serum cystatin C level between CAD 
and non-CAD patients, regardless of the presence of diabetic 
nephropathy. The cause of this discrepancy between studies is 
not clear, but several other studies have reported similar re-
sults to those of our study. Serum cystatin C has been used to 
predict chronic renal disease, but not CAD [8]. In a study of 
middle-aged subjects, carotid atherosclerosis was found to be 
associated with microalbuminuria but not with serum cystatin 
C level [9]. In addition, a recent study by Maahs et al. [10] also 
reported that, in persons without diabetes mellitus and having 
relatively normal renal function, increased cystatin C was as-
sociated with decreased, rather than increased, CAD progres-
sion. 
  In conclusion, we believe that serum cystatin C level is a 
useful marker for the assessment of renal function but is not a 
marker for CAD. However, our study is limited because it was 
a retrospective case-control study, the study sample was rela-
tively small, and we did not evaluate the associations among 
cystatin C level and other markers of inflammation or BMI. 
Further prospective studies with larger sample sizes are need-
ed to evaluate the relationship between serum cystatin C and 
cardiovascular disease. 
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